Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

Neonatal Care Unit receives donation to expand capacity
2015-10-28

  

With the best care and technology available,
the survival rate of premature
babies is about 85%. The neonatal intensive
care unit at the Universitas hospital can now
expand its capacity thanks to a donation of
R1 million by the Discovery fund.
From the left is Prof André Venter.
Head: Department of Paediatrics and
Child Health at the UFS, and mrs Ruth Lewin,
Head: Corporate Sustainability at Discovery. 

The smallest people need the greatest care. This care is being provided by the neonatal unit in the Children’s Wing of the Universitas Hospital. This project of the University of the Free State (UFS), under the leadership of Prof Andre Venter, has led to several miracles regarding child health since its inception.

Now, thanks to a donation of R1 million rand from the Discovery fund, this unit can expand its capacity and treat more premature babies.

About 14% of babies in South Africa are born before the 37th week of pregnancy. These babies are born with a very low birth weight, and are in need of critical care. The neonatal intensive-care unit at Universitas Hospital is currently equipped to take care of about 14 premature babies at a time, from birth to discharge. However, because of the high incidence of premature births in the hospital’s service area, the unit needs about 45 beds.

The aim of the Children’s Wing Project is to expand the neonatal intensive-care unit in order to meet the demands of the hospital’s service area, which reaches as far as the Southern Cape. The Discovery Fund recently donated R1 million to the project, which will be used to expand the capacity of the neonatal intensive-care unit.

“With the best care and technology available, the survival rate of premature babies is about 85%. Without this, half of all premature babies would die,” says Prof Venter, Head: Department of Paediatrics and Child Health at the UFS.

“This is the reason why private and public partnerships, such as the one with Discovery, are essential to make specialised services available to the most vulnerable people. Discovery has made a significant contribution to the project without which we would not have been able to expand the capacity of the unit



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept